Johnson & Johnson

Medtronic (NYSE: MDT) is scheduled to report fiscal fourth-quarter 2011 results before the markets open tomorrow, May 24. Analysts expect the medical device maker to announce that per-share earnings inched up 3 cents from a year ago to $0.93. That consensus estimate is unchanged from 60 days ago....

Goldman Sachs, which upgraded shares of Johnson & Johnson (NYSE: JNJ), is providing some color on the stock. “We are upgrading JNJ to Buy from Neutral as we switch to JNJ from BMY as the best underappreciated new product story in US Pharma,” Goldman Sachs writes. “After two years of earnings...

Goldman Sachs is switching its top new product story from Bristol-Myers Squibb Company (NYSE: BMY) to Johnson & Johnson (NYSE: JNJ) “as we believe BMY's superior new product story is now better appreciated while JNJ's remains under the radar screen.” “Hence, we downgrade BMY to Neutral and...

In conjunction with Goldman Sachs' healthcare upgrade of the MedTech sector to Attractive and its upgrade of Johnson & Johnson (NYSE: JNJ) to Buy, “we maintain our Attractive coverage view of the Managed Care sector and our Neutral view on of Healthcare Facilities.” Johnson & Johnson...

Goldman Sachs has upgraded Johnson & Johnson (NYSE: JNJ) from Neutral to buy and has raised the price target from $64 to $77.

According to J.P. Morgan, Johnson & Johnson (NYSE: JNJ) is turning positive. J.P. Morgan said that J&J has weathered a difficult couple of years, facing challenges on multiple fronts, including in 2008-09 generic competition for Risperdal and Topamax and the loss of significant DES share...

According to Bank Of America, Johnson & Johnson (NYSE: JNJ) has under performed the S&P since the beginning of 2010, but yesterday's (19th April) Q1 earnings report suggests a growth inflection point for JNJ (off a low base), which should end JNJ's weak relative stock performance. Bank Of...

Bank of America has raised the price objective on Johnson & Johnson (NYSE: JNJ) from $65 to $67 and maintains its Neutral rating.

According to Jefferies, Johnson & Johnson's (NYSE: JNJ) Q1:11 results and comments point toward improving pricing, volume, and utilization trends in select divisions. Jefferies reported that read-through is neutral-to-positive for competing companies in our universe including COV, BCR on the...

According to J.P. Morgan, Johnson & Johnson (NYSE: JNJ) has for the last several months publicly discussed its interest in executing one or more large acquisitions. J.P. Morgan reported that this is why J&J is not buying back stock, despite pressure from shareholders and the fact that it's...

Piper Jaffray reports that its analysis of IMS scrips through February indicate that Johnson & Johnson (NYSE: JNJ) US pharma sales are tracking slightly below expectations. “The company's recently launched products continue to perform well in terms of scrips and pricing, however this is more...

Johnson & Johnson's (NYSE: JNJ) announcement that it entered into a consent with the FDA effectively transforms the McNeil issues from a horizon of potentially 1-2 years to something closer to 4-5 years, Piper Jaffray reports. “In addition to lost product revenues, which totaled $900 mil for...

Piper Jaffray has lowered the price target on Johnson & Johnson (NYSE: JNJ) from $67 to $64 and maintains its Neutral rating.

Goldman Sachs has published a research report on Johnson & Johnson (NYSE: JNJ) and has lowered estimates on the company as a result of slow recovery on the company's MD&D and OTC businesses. In the report, Goldman Sachs writes "In 2010, JNJ's MD&D has slowed considerably due to the...

Piper Jaffray released its Medical Technology & Hospital Supplies update today after attending the Current Concepts in Joint Replacement meeting (CCJR). In a note to clients, Piper Jaffray writes, "We came away from the CCJR meeting with a mixed bag of feedback regarding the outlook for volume...